Axsome Therapeutics (AXSM) Misses Q1 EPS by 22c

Axsome Therapeutics (NASDAQ: AXSM) reported Q1 EPS of ($1.44), $0.22 worse than the analyst estimate of ($1.22). Revenue for the quarter came in at $75 million versus the consensus estimate of $74 million.

For earnings history and earnings-related data on Axsome Therapeutics (AXSM) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• SPS Commerce hires Morgan Stanley to explore sale amid activist push - Reuters
• After-Hours Stock Movers: FDX, CBRS, NKE